Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

MYND Life Sciences Inc C.MYND

Alternate Symbol(s):  MYNDF

Healthcare Biotechnology
MYND Life Sciences Inc., a life sciences-based neuro-pharmaceutical drug development company, advances medicines based on neuro-anti-inflammatory substances for depressive disorders through science and clinical trials in Canada and the United States. It focuses on the analysis of psilocin and psilocybin extracts, and analogs. MYND Life Sciences Inc. is based in Port Coquitlam, Canada.


CSE:MYND - Post by User

MYND Life Sciences Inc
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(8)
•••
  • Brice978X
Post by Brice978on Sep 13, 2021 8:40am
126 Views
Post# 33847591

$MYND

$MYND$MYND, these guys out of all thepyshceldic companies running clinical trials have some of the best chances for near term revenue with their biomarker.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities